Joint effects of CYP1A2*1F and CYP1A1*2A, CYP1B1 Leu432Val, AHRArg554Lys, CYP3A4*1B, COMTVal158Met and SULT1A1Arg213His on breast cancer risk
| . | AA . | . | AC . | . | CC . | . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | n* . | OR† (95% CI) . | n . | OR (95% CI) . | n . | OR (95% CI) . | |||||||
| CYP1A1*2A | |||||||||||||
| TT | 279/224 | 1.0 | 375/376 | 0.8 (0.6-1.0) | 82/112 | 0.7 (0.5-1.0) | |||||||
| TC | 259/274 | 0.9 (0.7-1.1) | 220/236 | 0.8 (0.6-1.1) | 6/10 | 0.5 (0.2-1.3) | |||||||
| CC | 92/107 | 0.8 (0.6-1.1) | 8/8 | 0.7 (0.3-2.0) | 1/0 | — | |||||||
| Pinteraction | 0.64‡ | ||||||||||||
| CYP1B1 Leu432Val | |||||||||||||
| LL | 274/237 | 1.0 | 267/237 | 0.8 (0.6-1.1) | 35/33 | 0.9 (0.5-1.5) | |||||||
| LV | 240/247 | 0.9 (0.7-1.1) | 211/225 | 0.8 (0.6-1.1) | 35/47 | 0.6 (0.4-1.1) | |||||||
| VV | 116/121 | 0.9 (0.7-1.3) | 125/158 | 0.8 (0.6-1.1) | 19/42 | 0.5 (0.3-0.9) | |||||||
| Pinteraction | 0.75 | ||||||||||||
| AHR | |||||||||||||
| RR | 368/375 | 1.0 | 303/318 | 0.9 (0.7-1.1) | 40/54 | 0.8 (0.5-1.2) | |||||||
| RL | 206/168 | 1.3 (1.0-1.7) | 223/226 | 1.0 (0.7-1.3) | 30/54 | 0.6 (0.4-1.0) | |||||||
| LL | 56/62 | 0.8 (0.6-1.3) | 77/76 | 0.9 (0.7-1.4) | 19/14 | 1.4 (0.7-2.8) | |||||||
| Pinteraction | 0.13 | ||||||||||||
| CYP3A4*1B | |||||||||||||
| AA | 537/461 | 1.0 | 469/439 | 0.8 (0.7-1.0) | 63/76 | 0.7 (0.5-1.0) | |||||||
| AG | 67/106 | 0.8 (0.5-1.1) | 81/120 | 0.8 (0.6-1.2) | 13/26 | 0.6 (0.3-1.2) | |||||||
| GG | 26/38 | 0.9 (0.5-1.6) | 53/61 | 1.1 (0.7-1.8) | 13/20 | 0.8 (0.4-1.8) | |||||||
| Pinteraction | 0.54 | ||||||||||||
| COMT Val158Met | |||||||||||||
| Val/Val | 242/248 | 1.0 | 239/245 | 0.9 (0.7-1.2) | 33/49 | 0.7 (04.-1.1) | |||||||
| Val/Met | 300/264 | 1.1 (0.8-1.4) | 273/281 | 0.9 (0.7-1.1) | 41/59 | 0.7 (0.5-1.1) | |||||||
| Met/Met | 88/93 | 0.9 (0.6-1.3) | 91/94 | 0.8 (0.6-1.2) | 15/14 | 1.0 (0.5-2.2) | |||||||
| Pinteraction | 0.71 | ||||||||||||
| SULT1A1 Arg213His | |||||||||||||
| Arg/Arg | 376/335 | 1.0 | 364/356 | 0.9 (0.7-1.1) | 51/82 | 0.6 (0.4-0.9) | |||||||
| Arg/His | 195/219 | 0.8 (0.6-1.1) | 192/216 | 0.8 (0.6-1.0) | 30/36 | 0.8 (0.5-1.4) | |||||||
| His/His | 59/51 | 1.0 (0.7-1.6) | 47/48 | 0.8 (0.5-1.3) | 8/4 | 2.1 (0.6-7.2) | |||||||
| Pinteraction | 0.22 | ||||||||||||
| . | AA . | . | AC . | . | CC . | . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | n* . | OR† (95% CI) . | n . | OR (95% CI) . | n . | OR (95% CI) . | |||||||
| CYP1A1*2A | |||||||||||||
| TT | 279/224 | 1.0 | 375/376 | 0.8 (0.6-1.0) | 82/112 | 0.7 (0.5-1.0) | |||||||
| TC | 259/274 | 0.9 (0.7-1.1) | 220/236 | 0.8 (0.6-1.1) | 6/10 | 0.5 (0.2-1.3) | |||||||
| CC | 92/107 | 0.8 (0.6-1.1) | 8/8 | 0.7 (0.3-2.0) | 1/0 | — | |||||||
| Pinteraction | 0.64‡ | ||||||||||||
| CYP1B1 Leu432Val | |||||||||||||
| LL | 274/237 | 1.0 | 267/237 | 0.8 (0.6-1.1) | 35/33 | 0.9 (0.5-1.5) | |||||||
| LV | 240/247 | 0.9 (0.7-1.1) | 211/225 | 0.8 (0.6-1.1) | 35/47 | 0.6 (0.4-1.1) | |||||||
| VV | 116/121 | 0.9 (0.7-1.3) | 125/158 | 0.8 (0.6-1.1) | 19/42 | 0.5 (0.3-0.9) | |||||||
| Pinteraction | 0.75 | ||||||||||||
| AHR | |||||||||||||
| RR | 368/375 | 1.0 | 303/318 | 0.9 (0.7-1.1) | 40/54 | 0.8 (0.5-1.2) | |||||||
| RL | 206/168 | 1.3 (1.0-1.7) | 223/226 | 1.0 (0.7-1.3) | 30/54 | 0.6 (0.4-1.0) | |||||||
| LL | 56/62 | 0.8 (0.6-1.3) | 77/76 | 0.9 (0.7-1.4) | 19/14 | 1.4 (0.7-2.8) | |||||||
| Pinteraction | 0.13 | ||||||||||||
| CYP3A4*1B | |||||||||||||
| AA | 537/461 | 1.0 | 469/439 | 0.8 (0.7-1.0) | 63/76 | 0.7 (0.5-1.0) | |||||||
| AG | 67/106 | 0.8 (0.5-1.1) | 81/120 | 0.8 (0.6-1.2) | 13/26 | 0.6 (0.3-1.2) | |||||||
| GG | 26/38 | 0.9 (0.5-1.6) | 53/61 | 1.1 (0.7-1.8) | 13/20 | 0.8 (0.4-1.8) | |||||||
| Pinteraction | 0.54 | ||||||||||||
| COMT Val158Met | |||||||||||||
| Val/Val | 242/248 | 1.0 | 239/245 | 0.9 (0.7-1.2) | 33/49 | 0.7 (04.-1.1) | |||||||
| Val/Met | 300/264 | 1.1 (0.8-1.4) | 273/281 | 0.9 (0.7-1.1) | 41/59 | 0.7 (0.5-1.1) | |||||||
| Met/Met | 88/93 | 0.9 (0.6-1.3) | 91/94 | 0.8 (0.6-1.2) | 15/14 | 1.0 (0.5-2.2) | |||||||
| Pinteraction | 0.71 | ||||||||||||
| SULT1A1 Arg213His | |||||||||||||
| Arg/Arg | 376/335 | 1.0 | 364/356 | 0.9 (0.7-1.1) | 51/82 | 0.6 (0.4-0.9) | |||||||
| Arg/His | 195/219 | 0.8 (0.6-1.1) | 192/216 | 0.8 (0.6-1.0) | 30/36 | 0.8 (0.5-1.4) | |||||||
| His/His | 59/51 | 1.0 (0.7-1.6) | 47/48 | 0.8 (0.5-1.3) | 8/4 | 2.1 (0.6-7.2) | |||||||
| Pinteraction | 0.22 | ||||||||||||
Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval.
No. cases/no. controls. Numbers of subjects vary due to missing information.
OR (95% CIs) adjusted for age at blood draw, age at menarche, parity and age at first birth.
P value derived from a likelihood ratio test comparing a model with main effects for the CYP1A2*1F genotype and the risk factor, and a model with main effects and interaction terms.